- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00577070
Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression
There is a general consensus of efficacy of TMS in treatment of major depression,yet results are not satisfying.A new coil ("H"-coil, recently invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) is supposed to be capable of stimulating deeper brain structures than conventional coils.TMS using this coil was named by its developers as "deep TMS" and will hence be refered to by this name.
So far, deep TMS have studied in Israel with promising sucssess in patients with Major depression (An on-going study).A safety study with good results have been recently published.The aim of this study is to reinforce initial results in major depression using deep TMS.
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Beer Yaacov, Israel, 70350
- Beer-Yaacov MHC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Right handed ,18-65 year old male or female subjects
- Diagnosed according to DSM-V-TR as suffering from Major depression using SCID interview
- Score of 22 or more in the Hamilton Depression Rating Scale (HAM-D24)
- The present depressive episode have been treated with at least 2 different anti-depressive drugs at peak doses for at least 6 weeks with not more than a partial response.Augmentation strategies may be included.
Exclusion Criteria:
Cardiac pacemaker implant, or a history of epilepsy, neurosurgery, or brain trauma patients suffering from chronic medical conditions of any sort:
- History of current hypertension
- History of seizure or heat convulsion
- History of epilepsy or seizure in first degree relatives
- History of head injury
- History of any metal in the head (outside the mouth)
- Known history of any metallic particles in the eye
- Implanted cardiac pacemaker or any intra-cardiac lines
- Implanted neuro-stimulators
- Surgical clips or any medical pumps
- History of frequent or severe headaches
- History of migraine
- History of hearing loss
- Known history of cochlear implants
- History of drug abuse or alcoholism
- Pregnancy or not using a reliable method of birth control (non-pregnancy will be proved by beta-HCG test)
- Systemic and metabolic disorders
- Inadequate communication skills or under custodial care.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: H1
Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS,20 minutes each session, to the left prefrontal cortex using H1 coil, in frequency of 20 HZ, with intensity of 120 % of motor threshold. H1-coil is an extracorporeal device positioned on the patient's scalp, designed to stimulate deep prefrontal brain regions, preferentially in the left hemisphere. The effective part of the coil, which has contact with the patient's scalp, includes 14 strips of 7-12 cm length. These strips are oriented in an anterior-posterior axis.This coil stimulates neuronal fibers in anterior-posterior orientation. During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas. |
Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry.
This method is based on creating pre determined magnetic fields, which alternate rapidly.
The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials.
The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain.
Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
|
Experimental: H2
Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS, 20 minutes each session, to the prefrontal cortex bilateraly using H2 coil, in frequency of 0.1 HZ, with intensity of 120 % of motor threshold.
H2-coil is designed to stimulate deep prefrontal brain regions bilaterally (without any preferencefor either hemisphere).
The effective part of the coil, which has contact with the patient's scalp, includes 10 strips of 14-22 cm length.These strips are oriented in a right-left direction (lateral-medial axis).This coil is destined to stimulate lateral-medial neuronal fibers.
During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas.
|
Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry.
This method is based on creating pre determined magnetic fields, which alternate rapidly.
The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials.
The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain.
Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treatment response defined as at least a 50% decrease in Hamilton Depression Rating Scale (HAM-D24). Remission is defined as below 8 in Hamilton Depression Rating Scale (HAM-D24)
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Oded Rosenberg, M.D., Beer Yaakov Mental Health Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMS-204CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depression
-
Stanford UniversityTerminatedMajor Depressive Disorder | Major Depressive Episode | Major Depressive Disorder, Recurrent | Major Depression Mild | Major Depression Moderate | Major Depression SevereUnited States
-
Hawler Medical UniversityCompleted
-
Centre Hospitalier Universitaire de BesanconH. Lundbeck A/SCompletedResistant Major DepressionFrance
-
First Affiliated Hospital of Zhejiang UniversityNot yet recruiting
-
University of PittsburghCompletedPostpartum Major DepressionUnited States
-
Si TianmeiUnknownMajor Depression DisorderChina
-
The Hong Kong Polytechnic UniversityNot yet recruitingHealthy | Major Depression in Remission
-
AstraZenecaCompletedNon-psychotic Unipolar Major DepressionArgentina
-
Ruijin HospitalTerminatedTreatment Resistant Major Depression DisorderChina
-
Zentrum für Integrative PsychiatrieGerman Research FoundationCompletedCognitive Performance in Major DepressionGermany
Clinical Trials on TMS
-
Hartford HospitalRecruiting
-
Carilion ClinicUnknown
-
University of Southern CaliforniaNot yet recruitingBinge-Eating Disorder
-
Emory UniversityCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedExecutive FunctionUnited States
-
Bayside HealthNational Health and Medical Research Council, AustraliaCompletedMajor Depressive DisorderAustralia
-
Bayside HealthCompleted
-
Centre Hospitalier St AnneNot yet recruitingTreatment Resistant Schizophrenia
-
Mclean HospitalMassachusetts General HospitalCompletedSchizophrenia | Schizoaffective Disorder | Bipolar Disorder IUnited States
-
NYU Langone HealthWithdrawn